ACADIA Pharmaceuticals Inc. (ACAD)
$
24.81
+0.42 (1.69%)
Key metrics
Financial statements
Free cash flow per share
1.1148
Market cap
4.2 Billion
Price to sales ratio
4.1192
Debt to equity
0.0685
Current ratio
2.9106
Income quality
0.8458
Average inventory
24.5 Million
ROE
0.3067
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
ACADIA Pharmaceuticals Inc. focuses on the development and commercialization of small molecule drugs to address the unmet medical needs in central nervous system disorders. The company’s net income ratio is 0.24 reflecting its profitability margin. Despite the investment in research and development, the company reported selling, general, and administrative expenses of $488,428,000.00 indicating its operational overhead costs. The net total of other income and expenses is $27,281,000.00 reflecting non-core financial activities. Furthermore, the company incurred an income tax expense of $31,624,000.00 indicating its tax obligations. The income before tax ratio is 0.27 reflecting the pre-tax margin. ACADIA offers NUPLAZID (pimavanserin) for treating hallucinations and delusions associated with Parkinson's disease psychosis, while its pipeline includes pimavanserin, currently under phase 3 development for Alzheimer's disease psychosis and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for Rett syndrome; ACP-044, an innovative first-in-class orally administered non-opioid analgesic under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, undergoing phase 1 development for schizophrenia and cognitive dysfunction in Alzheimer's. Founded in 1993, ACADIA is headquartered in San Diego, California. Currently, the stock is affordable at $24.42 making it suitable for budget-conscious investors. Additionally, the stock has a high average trading volume of 1,986,626.00 indicating strong liquidity. With a mid-range market capitalization of $4,197,032,451.00 the company is regarded as a steady performer. ACADIA Pharmaceuticals is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth in areas that address critical health challenges.
Is ACADIA Pharmaceuticals Inc. (ACAD) a good investment?
Investing in ACADIA Pharmaceuticals Inc. (ACAD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bullish outlook. Always conduct your own research before investing.
What is ACADIA Pharmaceuticals Inc. (ACAD)'s stock forecast?
Analysts predict ACADIA Pharmaceuticals Inc. stock to fluctuate between $13.40 (low) and $26.65 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is ACADIA Pharmaceuticals Inc.'s market capitalization?
As of 2025-11-26, ACADIA Pharmaceuticals Inc.'s market cap is $4,197,032,451, based on 169,166,967 outstanding shares.
How does ACADIA Pharmaceuticals Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., ACADIA Pharmaceuticals Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy ACADIA Pharmaceuticals Inc. (ACAD) stock?
To buy ACADIA Pharmaceuticals Inc. (ACAD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACAD. Place an order (Market, Limit, etc.).
What is the best time to invest in ACADIA Pharmaceuticals Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did ACADIA Pharmaceuticals Inc. perform in the last earnings report?
Revenue: $957,797,000 | EPS: $1.37 | Growth: -470.27%.
Where can I find ACADIA Pharmaceuticals Inc.'s investor relations reports?
Visit https://www.acadia-pharm.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for ACADIA Pharmaceuticals Inc.?
You can explore historical data from here
What is the all-time high and low for ACADIA Pharmaceuticals Inc. stock?
All-time high: $33.99 (2023-07-18) | All-time low: $12.24 (2022-06-21).
What are the key trends affecting ACADIA Pharmaceuticals Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
seekingalpha.com
ACADIA Pharmaceuticals Inc. ( ACAD ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Mark Schneyer - Executive VP & CFO Ponni Subbiah Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Okay. Good day, everybody.
zacks.com
Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.
seekingalpha.com
ACADIA Pharmaceuticals Inc. ( ACAD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Albert Kildani Catherine Owen Adams - CEO & Director Thomas Garner - Executive VP & Chief Commercial Officer Elizabeth Thompson - Executive VP and Head of Research & Development Mark Schneyer - Executive VP & CFO Conference Call Participants Ritu Baral - TD Cowen, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Brian Abrahams - RBC Capital Markets, Research Division So Youn Shim - UBS Investment Bank, Research Division Samuel Beck - Deutsche Bank AG, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Sean Laaman - Morgan Stanley, Research Division Tazeen Ahmad - BofA Securities, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Julian Hung - Stifel Nicolaus Canada Inc., Research Division Basma Radwan Ibrahim - Leerink Partners LLC, Research Division Poorna Kannan - Needham & Company, LLC, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Presentation Operator Good day, ladies and gentlemen, and thank you for standing by.
zacks.com
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago.
zacks.com
The mean of analysts' price targets for Acadia (ACAD) points to a 27.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) breached their fiduciary duties to shareholders. If you currently own Acadia stock and acquired shares on or before September 9, 2019, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here t.
prnewswire.com
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
prnewswire.com
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
prnewswire.com
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
See all news
